The Meaningful Function of the Emerging Clinical Targets-lncRNA MEG3 in Gastric Cancer

LncRNA MEG3, a tumor suppressor gene, is related to reducing the proliferation, migration, and invasion as well as apoptosis abilities of gastric cancer (GC), which is a promising therapeutic target in patients. We conducted a comprehensive search of the literature on Pubmed using the keywords lncRNA MEG3 and gas cancer from 2014 to the present. Here, we provide a systematic and comprehensive summary of existing knowledge of the lncRNAs MEG3 and reveal its biological function and specific mechanisms in gastric cancer. MEG3 is involved in many molecular mechanisms that inhibit the development and progression of gastric cancer. For example, MEG3 can inhibit the proliferation of gastric cancer cells by inhibiting the expression of miR-21, miR-665, miR-148, miR-208, etc. MEG3 inhibits gastric carcinogenesis by inhibiting the negative regulator MDM2, regulating the expression of tumor suppressor genes p53 and Rb gene, and managing PI3K/Akt and Wnt/beta-catenin signaling pathways. Additionally, gastric cancer patients with low MEG3 expression have poor prognosis, and transfection of MEG3 can improve the overall survival time of normal cells. Eventually, lncRNA MEG3 can be used as a biomarker or target for intervention, thereby providing new insights for gastric cancer therapy.

Automated summary

This study provides a comprehensive summary of the role and specific mechanisms of LncRNA MEG3 in gastric cancer, revealing that MEG3 can inhibit the proliferation and migration of gastric cancer cells and is involved in various molecular mechanisms that suppress gastric cancer development. Low expression of MEG3 is associated with poor prognosis in gastric cancer patients, while transfection of MEG3 can improve the overall survival time of normal cells.